Calamos S&P 500 Structured Alt Protection ETF - March CPSR
26.30 USD -0.01 (-0.03%)
Regular-session close
26.30 0.00 0.00%
After hours · Nov 13, 4:15 PM ET
26.30 Day range 26.30
24.80 52-week range 26.32
- YTD
- +4.42%
- 1 year
- +5.63%
News
zacks.com Calamos S&P 500 ETF (CPSR) Touches Fresh 52-Week High CPSR hits a fresh 52-week high as investors seek upside linked to the S&P 500 with full downside protection over a year.
benzinga.com Gelesis, Maker Of Weight Loss Pill, Concludes SPAC Deal; Trading Kickstarts Today PureTech Health plc (NASDAQ: PRTC) founded entity Gelesis Inc, maker of weight management aid, has completed its business combination with Capstar Special Purpose Acquisition Corp (NYSE: CPSR). The…
businesswire.com Gelesis®, the Maker of Plenity® for Weight Management, Will Debut as a Publicly Traded Company Following the Closing of Its Business Combination with Capstar BOSTON & AUSTIN, Texas--(BUSINESS WIRE)--Gelesis, the maker of Plenity®, an FDA-cleared weight management approach, announced today the completion of its business combination with Capstar Special…
businesswire.com Gelesis Adds Inogen Co-Founder and Former CFO Ali Bauerlein to Board of Directors and Audit Committee BOSTON--(BUSINESS WIRE)--Gelesis, a biotherapeutics company focused on excess weight and metabolic disorders and the maker of Plenity®, announced the appointment of senior financial executive Ali…
businesswire.com Have Your Cake and Eat It Too: Plenity® Creates Edible Dessert Billboard to Challenge Overly Restrictive Dieting Assumptions BOSTON--(BUSINESS WIRE)--Gelesis, the maker of Plenity®, an FDA-cleared weight management approach, has created an edible billboard in New York City’s Astor Place to challenge the idea that people…
businesswire.com Gelesis’ FDA-Cleared Weight Management Approach, Plenity®, Now Broadly Available and Leading Nutrition Authority Joy Bauer, MS, RDN, CDN, Joins as Chief Nutrition Officer BOSTON--(BUSINESS WIRE)--Gelesis, a consumer-focused biotherapeutics company, is proud to announce Plenity®, an FDA cleared weight management approach, is now broadly available across the United…
businesswire.com Gelesis Receives $30 Million Plenity Order from Ro BOSTON--(BUSINESS WIRE)--Gelesis announced today that leading U.S. direct-to-patient healthcare company Ro has placed a $30 million fully paid pre-order for the company’s first commercial product for…
businesswire.com Nature’s Scientific Reports Features Gelesis’ Novel and Foundational Biomimetic Platform for Treating Obesity and Conditions Related to Diet-Induced Gut Damage BOSTON--(BUSINESS WIRE)--Gelesis, a consumer-focused biotherapeutics company and the maker of Plenity®, announced today a publication in Nature’s Scientific Reports describing the genesis of the…
businesswire.com Two Senior Scientific Leaders at Gelesis Awarded Top Industry Honors BOSTON--(BUSINESS WIRE)--Gelesis, a consumer-focused biotherapeutics company and the maker of Plenity®, announced that two senior leaders in the company, Elaine Chiquette, Pharm.D., and Elizabeth…
benzinga.com FDA-Approved Weight Loss Drug Plenity's Parent Announces SPAC Deal: What Investors Should Know A SPAC deal announced Monday could help accelerate the manufacturing of a promising weight loss drug targeting over 150 million people. The SPAC Deal: Gelesis announced a SPAC merger with Capstar…
businesswire.com Gelesis, a Consumer-Focused Biotherapeutics Company and the Maker of Plenity®, to Become a Publicly Traded Company via Merger with Capstar Special Purpose Acquisition Corp. BOSTON & AUSTIN, Texas--(BUSINESS WIRE)--Gelesis, Inc. (“Gelesis” or the “Company”), a biotherapeutics company advancing biomimetic superabsorbent hydrogels to treat excess weight and metabolic…
businesswire.com Gelesis, a Consumer-Focused Biotherapeutics Company and the Maker of Plenity®, to Become a Publicly Traded Company via Merger with Capstar Special Purpose Acquisition Corp. BOSTON & AUSTIN, Texas--(BUSINESS WIRE)--Gelesis, Inc. (“Gelesis” or the “Company”), a biotherapeutics company advancing biomimetic superabsorbent hydrogels to treat excess weight and metabolic…
businesswire.com Capstar Special Purpose Acquisition Corp. Receives Expected Notice from NYSE Regarding Delayed Quarterly Report AUSTIN, Texas--(BUSINESS WIRE)--Capstar Special Purpose Acquisition Corp. (NYSE:CPSR.U; CPSR; CPSR WS) (the “Company”) today announced that, as expected, on May 25, 2021 it received a notice from the…
benzinga.com Stocks That Hit 52-Week Highs On Friday Friday's session saw 466 companies set new 52-week highs.